

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Ocumension Therapeutics
歐康維視生物

(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 1477)

INSIDE INFORMATION ANNOUNCEMENT

**TOPLINE RESULTS OF THE MONTH 36 PRIMARY ANALYSIS OF THE
GLOBAL MULTI-CENTRE PHASE III CLINICAL TRIAL OF OT-101 (0.01%
ATROPINE SULFATE EYE DROPS)**

This announcement is made by Ocumension Therapeutics (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09(2)(a) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the inside information provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

OT-101 (0.01% atropine sulfate eye drops) is a low-concentration atropine eye drop independently developed by the Group to retard, or slow down, the progression of myopia in children and adolescents. However, the instability of low-concentration atropine solutions has long been a technical barrier towards commercialization. OT-101 uses an innovative closed-loop split device of exclusive design to solve the stability problem of low-concentration atropine solution in neutral environment. Also, the appropriate pH value improves the comfort of patients being treated and medication compliance.

The board (the “**Board**”) of directors (the “**Directors**”) of the Company hereby announces that the Group was recently informed of the topline results of the Month 36 primary analysis of the global multi-center phase III clinical trial (the “**Phase III Trial**”) of OT-101. The Phase III Trial is a multi-center, randomized, double-blind, placebo-controlled, parallel-group clinical trial which enrolled 678 children and adolescents aged 4 to 15 years (450 in the OT-101 group and 228 in the control group; 170 participants were enrolled in the PRC) in eight countries, with a three-year dosing period and a total study duration of 48 months. The primary endpoint was the percentage of study eyes with myopic progression of ≥ 0.75 D at Month 36.

At Month 36, the percentage of study eyes with myopic progression of ≥ 0.75 D in the OT-101 group was significantly lower than that in the control group; the result met the pre-specified primary endpoint criterion for the China region of the Phase III Trial.

In terms of safety, the overall incidence of adverse events was comparable to that of the control group, while the incidence of suspected treatment-related adverse events was higher than that of the control group, predominantly photophobia, eye pain and conjunctivitis, among others, which are generally consistent with the known pharmacological effects of atropine. No unexpected safety signals were identified.

The results set out in this announcement are preliminary topline data and remain subject to final verification and complete statistical analysis. The Company will need to obtain a more complete clinical dataset before it is able to conduct further analyses, which include subgroup analyses by age, baseline refractive error and region. Plans for regulatory submissions in the United States, Europe, the PRC and other regions can only be determined upon completion of these analyses and discussions with the relevant regulatory authorities. The Company will continue to engage with the relevant regulatory authorities and provide further updates as appropriate. These analyses will take time to complete, and their outcomes remain subject to significant uncertainty. There can be no assurance that any regulatory submission will be accepted for review or that any regulatory approval will be obtained.

Cautionary statement: The Company cannot guarantee that OT-101 (0.01% atropine sulfate eye drops) will ultimately be successfully developed, marketed and/or commercialized. Shareholders and potential investors are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
Ocumension Therapeutics
Dr. Lian Yong CHEN
Chairman and Non-executive Director

Hong Kong, October 20, 2026

As of the date of this announcement, the Board comprises Mr. Ye LIU and Dr. Zhaopeng HU as executive Directors, Dr. Lian Yong CHEN, Mr. Yanling CAO and Dr. Qin XIE as non-executive Directors, and Ms. Beibei ZHUANG, Mr. Yiran HUANG and Mr. Zhenyu ZHANG as independent non-executive Directors.